Abstract: An end effector is disclosed that is configured for connection to a robotic unit used to manipulate a door of a vehicle (e.g., during vehicle painting). The end effector includes a base plate; a sensor that is supported by the base plate; and a piston that is configured for engagement with the door. The piston is operatively connected to an interrupter such that movement (displacement) of the piston causes corresponding movement (displacement) of the interrupter between a first position, in which the interrupter is positioned in alignment with a signal transmitted across the sensor to interfere with the signal and thereby interrupt circuit completion, and a second position, in which the interrupter is out of alignment with the signal transmitted across the sensor to permit circuit completion and thereby inform the robotic unit that the door is present and engaged with the end effector.

Abstract: An end effector is disclosed that is configured for connection to a robotic unit used to manipulate a door of a vehicle (e.g., during vehicle painting). The end effector includes a base plate; a sensor that is supported by the base plate; and a piston that is configured for engagement with the door. The piston is operatively connected to an interrupter such that movement (displacement) of the piston causes corresponding movement (displacement) of the interrupter between a first position, in which the interrupter is positioned in alignment with a signal transmitted across the sensor to interfere with the signal and thereby interrupt circuit completion, and a second position, in which the interrupter is out of alignment with the signal transmitted across the sensor to permit circuit completion and thereby inform the robotic unit that the door is present and engaged with the end effector.

Abstract: The invention relates to a Rho GTPase activator, such as namely the cytotoxic necrotizing factor 1 (CNF1), for use in preventing and/or treating infections by a pathogen in a patient in need thereof. The invention also relates to a Rho GTPase activator, such as CNF1, for use in preventing and/or treating pathologies associated with an infection by a pathogen in a patient in need thereof. For instance, the invention relates to a Rho GTPase activator for use in treating infections by bacteria in a patient in need thereof and also relates to a Rho GTPase activator for use in reducing or eliminating bacteremia in a patient in need thereof.

Abstract: A cruise chip having a plurality of decks, certain of the decks having a plurality of staterooms therealong, the plurality of spaced staterooms extending along one of the decks and a second plurality of spaced staterooms extending along another of the decks directly above the other of said decks, and a single central double height corridor extending inboard of the ship, each of the plurality of spaced staterooms and shared entryways coming from the single central corridor and leading into a pair of side by side staterooms, the corridor terminating in a transparent glass window spanning one the decks to the other of decks.

Abstract: A cruise chip having a plurality of decks, certain of the decks having a plurality of staterooms therealong, the plurality of spaced staterooms extending along one of the decks and a second plurality of spaced staterooms extending along another of the decks directly above the other of said decks, and a single central double height corridor extending inboard of the ship, each of the plurality of spaced staterooms and shared entryways coming from the single central corridor and leading into a pair of side by side staterooms, the corridor terminating in a transparent glass window spanning one the decks to the other of decks.